NCT05175625CompletedPhase 3
A Randomized, Two-Armed, Placebo-Controlled, Double-Blind, Parallel-Group Clinical Trial to Evaluate the Immunogenicity and Safety of a Booster Dose of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen)
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Cinnagen
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies
Study Overview
Brief Summary
This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co. A total of 300 adult individuals received a single dose of either the SpikoGen vaccine or the saline placebo in a 5:1 ratio at 4 to 9 months after the second dose of a COVID-19 vaccine of any type. The injection was given in the deltoid muscle of the non-dominant arm. On day 14, the trial was unblinded, and the participants in the placebo group received a booster dose of the SpikoGen vaccine. For immunogenicity assessments, blood samples were collected on days 0 and 14 from all participants and on days 90 and 180 from those in the vaccine group only. For safety assessments, all participants were followed up for six months.
Study hypotheses included:
- A booster dose of the SpikoGen COVID-19 vaccine is safe and tolerable in adult subjects.
- A booster dose of the SpikoGen COVID-19 vaccine induces strong immunogenicity against SARS-CoV-2 in adult subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female ≥18 years
- •Willing and able to comply with all study requirements, including scheduled visits, interventions, and laboratory tests
- •Healthy adults or adults in a stable medical condition, defined as not being hospitalized within 3 months prior to the screening visit
- •Subjects who have received two doses of a COVID-19 vaccine of any type between 4 to 9 months before the screening visit
Exclusion Criteria
- •Subjects with signs of active SARS-CoV-2 infection at the screening visit or within 72 hours prior to the screening visit
- •Subjects who have been diagnosed with a breakthrough infection after receiving two doses of a COVID-19 vaccine
- •Subjects with epilepsy or a history of febrile seizures
- •Subjects who receive immunosuppressive or cytotoxic medications.
- •Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products.
- •Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study.
- •Subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study.
- •Subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection.
- •Female Subjects who are pregnant or breastfeeding or have planned to become pregnant within one month after the study injection.
- •Subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period.
- •Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.
- •Subjects who have donated ≥450 mL of blood or blood products within 28 days prior to the screening visit.
Outcomes
Primary Outcomes
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies
Time Frame: 14 days after the booster dose
As measured by ELISA
Secondary Outcomes
- Incidence of unsolicited adverse events(For 14 days after the booster dose)
- Geometric mean concentration (GMC) for S1 binding IgG antibodies(Days 0, 14, 90, and 180)
- Percentage of participants with seroconversion for S1 binding IgG antibodies(14 days after the booster dose)
- Geometric mean fold rise (GMFR) for receptor-binding domain (RBD) binding IgG antibodies(14 days after the booster dose)
- Geometric mean concentration (GMC) for SARS-CoV-2 neutralizing antibodies(Days 0, 14, 90, and 180)
- Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies(14 days after the booster dose)
- Percentage of participants with seroconversion for receptor-binding domain (RBD) binding IgG antibodies(14 days after the booster dose)
- Change in T-cell IFN-γ secretion from baseline to 14 days after the booster dose(Days 0 and 14)
- Incidence of solicited adverse events(For 7 days after the booster dose)
- Incidence of serious adverse events (SAEs) and suspected unexpected serious adverse reaction (SUSARs)(For 6 months after the booster dose)
- Geometric mean fold rise (GMFR) for S1 binding IgG antibodies(14 days after the booster dose)
- Geometric mean concentration (GMC) for receptor-binding domain (RBD) binding IgG antibodies(Days 0, 14, 90, and 180)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Study With SAGE-547 for Super-Refractory Status EpilepticusSuper-Refractory Status EpilepticusNCT02477618Supernus Pharmaceuticals, Inc.132
Completed
Not Applicable
A Clinical Study to Evaluate Efficacy and Safety of a Cosmetic Product in the Treatment of Facial LinesFine LinesWrinklesPhotoagingNCT04545970Revision Skincare56
Completed
Phase 2
Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in FilipinosPediculosis CapitisNCT03286101United Laboratories120
Unknown
Phase 2
The Efficacy and Safety of Zhigancao Tang Granule for HFpEF of Qi-Yin DificiencyHeart Failure With Preserved Ejection FractionNCT04317339Shanghai University of Traditional Chinese Medicine122
Completed
Phase 3
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's DiseaseCrohn's DiseaseNCT01277666GlaxoSmithKline608